Presentation Title: A non-biologic nanoparticle paclitaxel (NBN-Pac) formulation (IG-001) with characteristics of an albumin-based formulation (nab-Pac). Poster Session D, Monday, February 25th, from 4:30 p.m. to 6:30 p.m. at the Hyatt Regency Maui in Maui, HI.
Dr. Motamed will present in vitro dissolution results and consolidated phase I and tumor accumulation data for our phase III-ready drug candidate, IG-001, a chemical polymer-bound nanoparticle paclitaxel formulation. The data were accumulated through a development program across five major cancer indications:
Clinical studies of IG-001 performed in the United States and other countries such as Korea and Russia, have demonstrated similar clinical activity as albumin-bound paclitaxel (Abraxane®) in patients with metastatic breast cancer, non-small cell lung cancer, advanced pancreatic cancer and ovarian cancer. IG-001 is currently approved and commercially available in Korea as Genexol PM®. These properties make IG-001 an ideal platform for personalized paclitaxel; where personalized dosing and patient selection are combined with the best paclitaxel nanoparticle formulation to potentially achieve safe and effective paclitaxel chemotherapy.
About AACR/JCA joint conference on Breakthroughs in Basic & Translational Cancer Research Conference (2013): More than 20 years ago, the American Association for Cancer Research and the Japanese Cancer Association held their first of eight joint conferences. These meetings have been aimed at bringing outstanding American and Japanese researchers together with two goals. The first is to provide a forum for discussion of the latest advances in the broad field of cancer research, both translational/
The Ninth Joint Conference continues to extend this tradition. The 12 conference sessions will feature outstanding speakers covering topics ranging from basic science to therapeutics, including prevention, epigenetics and other important areas. Thus, the conference will take a broad view of contemporary cancer research that is intended to be of interest to basic and clinical investigators. The organization and timing of the platform and poster sessions have been designed to maximize interactions. The conference organizers believe that this meeting will catalyze many new collaborations, just as its predecessors have done.
About IGDRASOL: IGDRASOL is a developer of personalized nanoparticle paclitaxel therapy. At IGDRASOL, we are taking advantage of the convergence of technologies that make personalized paclitaxel therapy possible. Our platform is IG-001 (chemical polymer-bound nanoparticle paclitaxel), a next generation nanoparticle paclitaxel with clinical activity demonstrated to date to be at least on par with Abraxane. IG-001 is free of issues with Cremophor and albumin; excipients for Taxol® (Cremophor-based paclitaxel) and albumin-bound paclitaxel (Abraxane®), respectively. It combines the manufacturing simplicity of Taxol with the albumin-mediated transport properties of Abraxane. IGDRASOL will be conducting registration trials for multiple cancer indications.
IG-001(chemical polymer-bound nanoparticle paclitaxel) is approved in Korea and marketed by Samyang Biopharmaceuticals as Genexol-PM®. IGDRASOL, together with its corporate partners, are also developing quantitative point-of-care testing solutions for biomarker testing and paclitaxel therapeutic drug monitoring—technologies which would be instrumental in personalizing paclitaxel therapy. The executives of IGDRASOL are a group of pharmaceutical veterans who believe that personalized nanoparticle paclitaxel therapy will present a paradigm shift in the delivery of chemotherapeutic agents. To learn more about our mission please visit
our website (http://www.igdrasol.com).
Genexol-PM® is a registered trademark of Samyang Corporation. Abraxane® is a registered trademark of Celgene, Inc. Taxol® is a registered trademark of Bristol-Myers Squibb, Inc.
Vuong Trieu, Ph.D.
Chief Executive Officer
Forward-Looking Statements :
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. These statements are based on management's current beliefs and expectations and our business is subject to numerous risks and uncertainties. Some of the risks include that we have a limited operating history and limited financial resources, that our product candidates have not completed clinical development and have not received and may not ever receive regulatory approval for commercialization. As a result of risks affecting our business, actual results or events could differ materially from the plans, projections and expectations set forth in our forward-looking statements, therefore, readers are cautioned not to place undue reliance on such forward-looking statements. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this presentation except as required by law.